Dr. Reddy’s Laboratories announces the launch of Clofarabine Injection in the U.S. Market

Hyderabad: Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar® (clofarabine) Injection in the United States market, approved by the U.S. Food & Drug Administration (USFDA).

The Clolar® brand and generic had U.S. sales of approximately $53 million MAT* for the most recent twelve months ended in September 2017, according to IMS Health*.

Dr. Reddy’s Laboratories’ Clofarabine Injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL). Clolar® is a registered trademark of Genzyme Corporation.